US FDA authorises Pfizer-BioNTech booster shots for kids aged 12-15

The US FDA has expanded the emergency use authorisation for the Pfizer-BioNTech Covid-19 vaccine boosters to children aged 12 to 15.

Pfizer
A medical worker prepares to dilute a vial of Pfizer-BioNTech vaccine at a coronavirus disease vaccination center in Singapore (Photo: Reuters)
IANS Washington
1 min read Last Updated : Jan 04 2022 | 10:27 AM IST

The US Food and Drug Administration (FDA) has expanded the emergency use authorization for the Pfizer-BioNTech Covid-19 vaccine boosters to children aged 12 to 15.

On Monday, the FDA also shortened the time for booster shots from at least six months after completion of the initial series to at least five months, for everyone aged 12 and older, reports Xinhua news agency.

The agency has determined that the protective health benefits of a single booster dose of the Pfizer-BioNTech Covid-19 vaccine to provide continued protection against the virus and the associated serious consequences outweigh the potential risks in individuals aged 12 to 15.

The agency said that it found "no new safety concerns" following a booster shot in young teenagers, and that there were no new reports of two types of heart inflammation called myocarditis or pericarditis linked to the boosters.

The decision came as the Omicron variant is spreading rapidly across the US and has led to record high hospitalisations among younger people.

--IANS

ksk/

 

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :US Food and Drug AdministrationPfizerCoronavirus Vaccine

First Published: Jan 04 2022 | 10:27 AM IST

Next Story